Why Puma Biotechnology Inc. Shares Were Creamed

Puma Biotechnology shares face a double whammy following the annual ASCO conferences. Find out what's next for Puma and shareholders.

Jun 2, 2014 at 2:07PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Puma Biotechnology (NYSE:PBYI), a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer, plunged as much as 25% after reporting phase 2 data on PB272 (also known as neratinib) at the American Society for Clinical Oncology's annual meeting over the weekend.

So what: Puma is actually being dealt a double blow today with investors souring on its reported data as well as punishing the company for a rival's failure.

Beginning with Puma's phase 2 results, the company reported data only from its first cohort of 40 patients which have metastatic breast cancer that had metastasized to the brain and received PB272 as a monotherapy. As the results show, a number of these patients experienced grade 3 diarrhea associated with PB272: 29% of patients not taking any therapy meant to curb neratinib-related diarrhea, and 21% of patients given a low-dose loperamide to counter neratinib-related diarrhea. Perhaps more damaging was that despite the data being described as "positive" by Puma, only three of 40 patients had a partial response, while four demonstrated prolonged stable disease (more than six months), and 12 experienced stable disease equating to six months or less. Median progression-free survival was 1.9 months, while median overall survival was 8.7 months. Clearly, investors were expected partial response figures to be more robust.

In addition, GlaxoSmithKline (NYSE:GSK) reported the failure of its metastatic breast cancer therapy, Tykerb, to meet its primay endpoint of improved disease-free survival in a phase 3 study in combination with Herceptin for HER2-positve early stage breast cancer. The thought here from investors is that if Glaxo's Tykerb is having difficulty in the neoadjuvant setting for metastatic breast cancer, then PB272 may have just as difficult a time.

Now what: Today is certainly a batten down the hatches kind of day if you're a Puma Biotechnology shareholder – but it's also not the end of the world, either. Keep in mind that Puma is actually running three mid-stage studies on PB272 and only had data at ASCO to present on one, so there's still plenty of time left for it to potentially demonstrate that PB272 is better than existing therapies on the market. I'd be lying if I said I wasn't disappointed with the low partial response rate in its 40-patient study, but brain metastases are inherently difficult to fight to begin with. The factor I would watch more would be those grade 3 diarrhea-related events. Safety is paramount to the Food and Drug Administration, and a considerably higher degree of adverse events could knock PB272 down the totem the pole. Moving forward I'd suggest keeping Puma on your watchlist but sticking the sidelines for the time being.

Puma may offer plenty of potential, but even it's unlikely to be able to keep pace with this top stock over the long run
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers